Drug intelligence / Profile preview

Gansulin

Development stage: Unknown
Lead developer: Gan & Lee Pharmaceuticals
Modality: Peptides, Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous, Intramuscular

Overview

Gansulin is a brand of human insulin products marketed by Gan & Lee Pharmaceuticals, China's largest domestic insulin manufacturer. It encompasses various formulations, including short-acting human insulin (Gansulin R) and biphasic human insulin (Gansulin M30), which is a mixture of soluble and isophane insulin. These products are utilized in the management of diabetes by regulating glucose metabolism.

Brand names: Gansulin
Other names: Gensulin

Targets

IGF-1R (Insulin-like growth factor 1 receptor)INSR (Insulin receptor)

Beyond the preview

Go deeper on Gansulin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gansulin.

Explore the full profile